BRAF and neoplasm: Even more, TERT amplification was able to prognosticate a poor survival independently of other variables that also exhibited predictive value such as age ≥ 55 years old, extrathyroidal extension, and BRAF mutations. Similarly to what have seen in tumor recurrence, the presence of BRAF mutations on PTC cells decreased de risk of dying due to the tumor (RR/HR 0.333).